Navigating Convergent Pricing Headwinds: A Strategic Assessment of Policy Risk and Value Defence in the U.S. Biopharmaceutical Market

I. Executive Summary: The Structural Reordering of U.S. Drug Pricing

The U.S. pharmaceutical market is undergoing an unprecedented structural transformation driven by the convergence of two powerful, distinct government pricing mandates: the statutorily grounded negotiation authority established by the Inflation Reduction Act (IRA) and the politically accelerated price alignment dictated by the Most-Favored-Nation (MFN) Executive Order (EO) and the related TrumpRx platform. This confluence introduces profound volatility, shifting the U.S. from its historical role as the global premium pricing anchor to a system characterized by government-managed price floors and mandatory price compression.

A. Synthesis of Dual Policy Pressure

The IRA’s core mechanism empowers the Centers for Medicare & Medicaid Services (CMS) to negotiate a Maximum Fair Price (MFP) for selected high-cost drugs in Medicare Parts B and D.¹ This negotiation framework fundamentally shortens the effective economic lifecycle of targeted products, acting as an accelerated Loss of Exclusivity (LOE) date, typically 9 years for small molecules and 13 years for biologics.² Initial outcomes from the first round of negotiations confirm the severity of this policy, with reductions averaging a minimum of 38% off 2023 list prices for the inaugural cohort of drugs.³

Concurrently, the revived MFN framework aims to align U.S. prices with the lowest prices paid in comparable developed nations.⁴ This policy, driven by executive fiat, relies on high-stakes, transactional agreements, exemplified by the voluntary pricing concessions secured from major manufacturers (Eli Lilly and Novo Nordisk) for high-volume products like GLP-1 receptor agonists.⁵ The introduction of the TrumpRx direct-to-consumer (DTC) portal further destabilizes traditional distribution channels by facilitating out-of-pocket purchases at these new, reduced reference prices.⁶

B. Strategic Imperatives for Global Biopharma

To navigate this rapidly constricting environment, biopharmaceutical companies must immediately adopt three strategic imperatives:

1. Defense Against Erosion: Manufacturers must pivot capital allocation and R&D investment strategies to anticipate and mitigate the shortened economic lifecycle imposed by the IRA.² This involves rigorous, early assessment of therapeutic differentiation required to survive negotiation.

2. Advanced Value Demonstration: The CMS negotiation process must be treated as the de facto U.S. Health Technology Assessment (HTA) body. This necessitates the generation of high-quality, comparative effectiveness data, starting earlier in development, to proactively address the criteria CMS uses to determine therapeutic value.⁷

3. Operationalizing Value-Based Pricing (VBP): Innovative contracting models, especially Indication-Specific Pricing (ISP), are crucial tools for defending segmented value. However, the viability of these models remains contingent upon solving persistent regulatory hurdles, particularly those related to the Medicaid Best Price (BP) rule, which currently penalizes performance-based risk-sharing agreements.⁹

II. The New Pricing Equilibrium: Juxtaposing Statutory and Executive Mandates

The contemporary U.S. pricing environment is defined by the duality of the IRA, a statutory mechanism focused on long-term systemic savings, and the MFN framework, an executive instrument engineered for immediate, high-profile price reductions.

A. The Inflation Reduction Act (IRA): Mechanism and Financial Imprints

The IRA grants the HHS Secretary, through CMS, the explicit authority to regulate the prices of certain single-source, high-cost Medicare Part D and B drugs.¹ This authority did not exist prior to the IRA, which was enacted after initial attempts at implementing MFN through executive orders.¹

The Maximum Fair Price (MFP) Negotiation Framework

The selection process for negotiation specifically targets products at the point of maximum value realization, often when Medicare expenditures are highest.⁸ Crucially, the negotiation process effectively functions as a new, accelerated Loss of Exclusivity (LOE) date for the Medicare channel, triggering at 9 years for small-molecule drugs and 13 years for large-molecule biologics.² This shortening of the market exclusivity window compresses the net present value (NPV) of pipeline assets, mandating higher clinical differentiation to justify R&D investment.

Quantifying the Initial Financial Shock

Analysis of the inaugural round of negotiation results, set to be effective in 2026, confirms the profound financial impact intended by the legislation. The negotiated prices represent a minimum average reduction of 38% off the 2023 list price, saving Medicare beneficiaries an estimated $1.5 billion annually in out-of-pocket costs and saving the Medicare program $6 billion per year.³

Specific case examples illustrate the scale of mandated price compression:

• Stelara (Janssen/J&J) for psoriasis and Crohn’s disease saw its negotiated price drop to $4,695, significantly lower than the $13,836 list price.¹¹

• Januvia (Merck), a diabetes drug, had its list price of $527 reduced to $113.¹¹

• Jardiance (Boehringer Ingelheim and Eli Lilly), a high-expenditure diabetes/heart failure drug with over $7 billion in Medicare spending ⁸, was negotiated down from $573 to $197.¹¹

These substantial reductions affect products central to global biopharma portfolios (e.g., Entresto, Xarelto, Fiasp/NovoLog) and establish a new fiscal reality for products approaching their negotiation window.⁸

The Spillover Effect on the Commercial Market

The public disclosure of negotiated Maximum Fair Prices is not confined to Medicare. These prices inevitably serve as public benchmarks, creating a new, visible reference point. Industry analysis suggests that manufacturers are unlikely to offer significantly deeper discounts in the employer-sponsored or commercial sectors while simultaneously absorbing mandated Medicare cuts.² Consequently, PBMs and commercial payers will be strongly pressured to incorporate these newly established low reference points, extending the MFP price floor across the entire U.S. market and accelerating margin compression.²

B. The Most-Favored-Nation (MFN) Framework and TrumpRx: Volatility as Policy

The MFN Executive Order, aiming to eliminate global free riding, mandates that the U.S. should not pay more for prescription drugs than the lowest price paid in any comparable developed nation.⁴ This policy aims for immediate price reductions, targeting cuts potentially ranging from 30% to 80%.¹³

The GLP-1 and Insulin Case Studies

The most visible deployment of MFN pricing has occurred in the high-expenditure GLP-1 and insulin markets, driven by voluntary agreements with key manufacturers. Eli Lilly and Novo Nordisk agreed to dramatically reduce prices for their flagship GLP-1 receptor agonists and insulin products.⁵

Key pricing concessions include:

• The monthly price for high-demand GLP-1 drugs, such as Ozempic and Wegovy, will fall from approximately $1,000 and $1,350, respectively, to $350 when purchased through the new TrumpRx platform.⁵

• Future oral GLP-1 formulations in the pipeline (e.g., the Wegovy pill) will be priced at an initial dose of $150 per month through TrumpRx.⁵

• Common insulin products from Novo Nordisk, like NovoLog and Tresiba, will be priced at $35 per month of supply.¹⁵

These price reductions were inextricably linked to a substantial policy trade-off: expanded Medicare and Medicaid coverage for anti-obesity medications for adults, coverage previously restricted or non-existent.⁵ This regulatory maneuver highlights that MFN operates not solely as a pricing mechanism, but as a strategic tool for the executive branch to grant immediate market access (volume) in exchange for significant price concessions (control). This ability to accelerate market changes through executive fiat is a crucial dynamic that operates independently, and often faster, than the statutory IRA process.

The Operational Disruptor: TrumpRx

The TrumpRx platform, set to launch in 2026, facilitates direct-to-consumer (DTC) purchasing at these discounted MFN rates, thereby bypassing traditional healthcare intermediaries, including Pharmacy Benefit Managers (PBMs) and insurance plans.⁶

This creates immense channel conflict. While manufacturers may gain a path to reduce intermediation costs, they must concurrently manage a parallel distribution mechanism while dealing with the fallout of publicly established low reference prices. Furthermore, major pharmaceutical leaders have warned that importing foreign price controls and inserting them into the existing U.S. system, which retains complex insurance and PBM intermediation, risks embracing the "worst of two worlds": the potential low productivity of ex-U.S. biopharma sectors combined with the high out-of-pocket costs and distorted pricing of the U.S. insurance market.⁴ The system is mandating lower prices without structurally guaranteeing the broad, hurdle-free access found in the referenced foreign systems.

Background Risk Multiplier: Inflation

The pricing challenges posed by IRA and MFN are compounded by broader macroeconomic pressures. High inflation, as measured by the headline Consumer Price Index (CPI), was elevated in 2025, reaching 3.0 percent on a twelve-month basis, with annualized growth up to 4.1 percent in early 2025.¹⁷ High CPI is the primary metric against which the IRA calculates required manufacturer rebates for price increases.² Consequently, the simultaneous pressure of mandated cuts (IRA/MFN) and strict price inflation controls across all payer channels represents a significant constraint on gross and net revenue growth.

Comparative Analysis of U.S. Drug Pricing Mandates (IRA vs. MFN)

III. Erosion of Exclusivity and Global R&D Strategy Recalibration

The dual imposition of IRA and MFN policies demands a fundamental recalibration of R&D portfolio strategy and global market sequencing, driven by significant compression of asset NPV.

A. Modeling the Impact on Innovation and Capital Allocation

NPV Compression and R&D Strategy

The shortening of the effective economic lifecycle under the IRA—functioning as an accelerated LOE—necessitates a higher internal hurdle rate for R&D projects. This forces a prioritization of assets demonstrating exceptional therapeutic differentiation, capable of commanding a premium price and delivering a rapid return before the 9- or 13-year negotiation trigger.²

Industry analysis has quantified the potential long-term damage of these policies. For example, reports claimed that the MFN policy alone could result in substantial job losses (1.98 to 2.2 million jobs, or 40% of U.S. biopharma industry jobs) and cut clinical trial activity by up to 75%.¹³ Although overall R&D investment remained relatively strong in 2024 (increasing over 10% from 2023) ¹⁸, dealmaking shifted markedly toward smaller, earlier-stage assets. This decline in the volume and value of deals suggests a conscious risk-management strategy to avoid large, late-stage acquisitions that are highly exposed to near-term IRA negotiation risk.¹⁸

The Orphan Drug Disincentive

The IRA contains specific provisions that actively disincentivize indication expansion for therapies with orphan drug designation. If a manufacturer adds a secondary indication, the therapy risks losing its protected orphan status, thereby becoming eligible for price negotiation.¹⁹ Modeling suggests that any new indication would require a minimum of a 40% increase in incremental revenue just to offset the projected losses resulting from subsequent price negotiation.¹⁹ This forces R&D teams to prioritize narrowly focused approvals over exploring broad therapeutic applicability, potentially limiting patient benefit for existing molecules.

B. The Contagion Effect: U.S. Price Floor as Global Ceiling

The most critical long-term consequence for global biopharma lies in the inevitable erosion of international pricing power. The newly negotiated MFP and MFN prices, once publicly accessible, will be strategically leveraged by international HTA bodies and national payers operating under external reference pricing (ERP) systems.⁴

Post-DPNP (Drug Price Negotiation Program) negotiation, payers in Europe and other HTA markets are expected to reference the reduced U.S. drug prices and demand commensurate discounts.¹⁹ This dynamic accelerates the downward pressure on global net prices. Manufacturers are consequently incentivized to maximize profit before the IRA negotiation trigger, potentially leading to high launch prices globally.¹⁹ However, this strategy risks creating immediate friction with foreign HTA bodies, which may demand additional deep discounts based on the high, short-term U.S. profit margins generated prior to negotiation.¹⁹

The severe political focus on high-volume, chronic care markets, such as the targeting of GLP-1s under MFN ⁵, underscores the immediate threat to these therapeutic areas. This pressure compels companies like Eli Lilly and Novo Nordisk to accelerate R&D efforts in next-generation molecules, such as oral formulations, that can sustain rapid volume expansion at dramatically lower, predetermined price points ($150 per month for initial oral GLP-1 dose).⁵ Concurrently, there is an observable strategic shift of capital toward highly specialized, high-unmet-need areas (e.g., cell and gene therapy) where initial patient volumes are lower and value justification is inherently stronger, offering temporary insulation from the IRA’s volume-based negotiation triggers.

One potential consequence of this mandated price compression is an indirect economic shift. To compensate for revenue erosion in negotiated biologics and branded drugs, manufacturers may increase pricing on non-negotiated assets, including certain existing generics or biosimilars.¹⁹ This represents a complex financial backstop strategy designed to recover lost margin elsewhere in the portfolio.

IV. The Evolution of Value Assessment: From ICER to CMS HTA Convergence

The U.S. pricing landscape is increasingly defined by Health Technology Assessment (HTA). While previously limited to private bodies like the Institute for Clinical and Economic Review (ICER) and Payer & Therapeutic (P&T) committees, the IRA mandates that CMS perform a comprehensive value assessment, effectively institutionalizing a form of HTA at the federal level.

A. Deconstructing the CMS Negotiation Criteria and Value Inputs

The IRA negotiation framework requires CMS to consider extensive evidence, including comparative effectiveness, clinical benefit, the costs of research and development, and the extent to which the drug addresses an unmet medical need.⁷ This statutory mandate formally aligns the U.S. reimbursement process with key principles used by global HTA organizations.²⁰

Value Metrics and Subpopulations

Although the Quality-Adjusted Life Year (QALY) is politically sensitive and statutorily constrained for use by CMS, the negotiation process still demands demonstrable metrics of health gain and cost-effectiveness.⁷ Private U.S. HTA bodies, such as ICER, utilize cost-effectiveness thresholds, typically around $96,000 per QALY ²¹, and incorporate concepts like Equal-Value Life Years (evLY) to quantify unmet need.²² This methodology provides the foundational language that manufacturers must master to articulate value during negotiation, regardless of CMS’s explicit terminology restrictions.

A key specificity of the IRA is the requirement for CMS to consider the drug’s effects on specific patient populations, including the elderly, the disabled, and the terminally ill.⁸ This focus elevates the importance of targeted evidence generation. Manufacturers must proactively generate high-quality Real-World Evidence (RWE) demonstrating superior outcomes specifically within these complex patient groups to ensure the value assessment captures the total societal benefit.¹⁹

B. Mapping Global HTA Divergence and the Unified Dossier Imperative

Variability in Comparator Selection

Global HTA systems, while sharing core methodological elements, exhibit significant variability. A comparison of HTA bodies like the Canadian Agency for Drugs and Technologies in Health (CADTH) and the National Institute for Health and Care Excellence (NICE) demonstrates wide variation in the selection of therapeutic alternatives used in cost-effectiveness modeling.²³ If CMS selects an unfavorable or overly narrow comparator, the resulting MFP will be aggressively low, undermining the manufacturer's value argument.

The influence of international HTA practice is pervasive. Agencies such as NICE (UK), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Institute for Quality and Efficiency in Health Care (IQWiG) in Germany are recognized as influential catalysts for global HTA reform.²⁴ Companies routinely incorporate HTA requirements into the evidence generation plan for approximately 63% of their products, acknowledging the global nature of evidence demands.²⁰ NICE, in particular, is recognized for consistently reporting more comprehensive methodological information than other major bodies.²⁵

Recommendation for the Global Core Value Dossier

The mandatory nature of IRA value assessment means that health economic outcomes research (HEOR) has transitioned from a supporting market access function for ex-U.S. markets to a core strategic necessity for U.S. commercial defense. To mitigate the risk of adverse negotiation outcomes, manufacturers must develop a "Global Core Value Dossier." This dossier must be designed to satisfy the most rigorous methodological and transparency standards, such as those demonstrated by NICE ²⁵, creating a consistent, defensible value argument that anticipates and counters unfavorable comparator selections made by CMS.

Given that the IRA negotiation process occurs post-approval (9–13 years), manufacturers have a significant opportunity to conduct rigorous, post-launch comparative effectiveness studies utilizing RWE, especially in large populations like Medicare beneficiaries.¹⁹ This RWE generation provides a crucial pathway to refine and bolster the value story beyond the initial regulatory dossier, establishing clinical and economic superiority necessary to defend pricing against statutory compression.

Global HTA Methodological Context for CMS Negotiation

V. Mitigating Risk Through Value-Based and Innovative Contracting

Innovative contracting, particularly Value-Based Pricing (VBP), serves as a necessary strategic countermeasure against uniform price mandates. VBP, also known as outcomes-based or performance-based contracting, ties the price or reimbursement of a drug to its measured clinical or economic performance in the real world.²⁶ This approach allows manufacturers to align the gross cost of medicines with their actual value, providing a mechanism to defend premium prices by taking on performance risk.²⁷

A. Strategic Imperative for Value-Based Pricing (VBP)

Successful defense against IRA and MFN requires manufacturers to scale VBP models beyond limited pilot programs. Key models for strategic deployment include:

1. Outcomes-Based Rebates: The most common approach, where the manufacturer provides a rebate if pre-agreed clinical or cost-effectiveness metrics are not achieved.²⁶

2. Indication-Specific Pricing (ISP): This model sets differential prices for a single drug based on its varying effectiveness and value across multiple FDA-approved indications.²⁶ ISP is critical for countering the IRA’s negotiation structure, which typically threatens to reference the entire product price based on its lowest-value indication.

3. Shared Savings: Agreements where manufacturers share in net cost savings if the drug's use leads to a measurable reduction in total healthcare costs, such as fewer hospitalizations.²⁹

The specific vulnerability of high-volume therapeutic areas, demonstrated by the MFN targeting of GLP-1s, emphasizes the need for aggressive ISP adoption.⁵ If future GLP-1 approvals include high-value indications like significant cardiovascular (CV) risk reduction, ISP is the only viable strategy to prevent the newly established low MFN price for obesity from cannibalizing the revenue potential of the higher-value CV indication.

B. Navigating Legal and Regulatory Friction: The Best Price Barrier

Widespread VBP adoption remains heavily constrained by the regulatory environment, primarily the requirements of the Medicaid Drug Rebate Program (MDRP).

The Best Price Conundrum

The MDRP’s Best Price (BP) rule is designed to ensure that Medicaid obtains discounts at least as large as those available to most commercial purchasers.¹⁰ Historically, this rule has been the most significant impediment to VBP.³⁰ If a VBP agreement with a commercial payer results in a large rebate due to failure to meet an outcome metric, that negative outcome could trigger an unmanageable BP liability for the manufacturer across the entire Medicaid program.⁹

Regulatory Maneuvers and Ambiguity

CMS has attempted to alleviate these barriers by adopting a broad definition of Value-Based Purchasing (VBP) and proposing flexibilities regarding BP reporting.⁹ However, the legal and operational clarity remains insufficient for widespread adoption. Concerns persist that allowing manufacturers to report a variable range of prices in VBP arrangements could ultimately lead to lower drug rebates paid by manufacturers and higher Medicaid prescription drug costs, inviting political scrutiny and potential policy reversal.¹⁰ Furthermore, legal uncertainty regarding the application of Anti-Kickback Statute (AKS) safe harbors remains a hurdle for indication-specific pricing agreements.³¹

C. Technology and Data Infrastructure: The Enabling Foundation

Scaling VBP and ISP requires sophisticated technological infrastructure capable of reliable data tracking and performance validation.

RWE, Artificial Intelligence (AI), and digital health solutions are rapidly maturing to provide the necessary transparency and administrative capacity.³² This integration is essential for making value-based contracts practical, credible, and scalable.³² However, operational hurdles remain significant, including the complexity of data tracking, high administrative burdens, and the difficulty of accurately attributing clinical outcomes in patients utilizing multiple treatments simultaneously.²⁶

For innovative contracting to succeed, investment in RWE infrastructure must be viewed not merely as a regulatory requirement (as codified by the 21st Century Cures Act regarding RWE use for FDA approvals ³³), but as a core commercial contracting asset. Successful VBP execution requires managed care expertise capable of analyzing clinical efficacy data, health economics, and claims data to structure auditable contracts that minimize regulatory and financial risk.³⁰

VI. Strategic Recommendations for Biopharma Leadership

The converging pricing pressures mandate immediate, comprehensive strategic adjustments across the enterprise.

A. Financial Strategy: Capital Protection and Forecasting

1. Mandatory Risk Convergence Modeling: Implement advanced scenario planning that explicitly models the complex financial intersection of IRA-MFP and MFN-TrumpRx. Financial projections must assume that MFN price points for high-volume products act as a strong gravitational pull, setting the minimum net price expectation across all commercial and governmental channels.

2. Dynamic Pricing Architecture: Transition pricing models to actively support segmentation. Indication-Specific Pricing must be implemented where legally and operationally feasible to partition revenue streams and insulate high-value clinical indications from the price erosion mandated for lower-value indications.²⁶

3. Aggressive Cost of Goods Sold (COGS) Management: Invest aggressively in manufacturing process efficiency and supply chain resilience.³⁴ Sustaining margins in a constrained pricing environment requires continuous optimization of production costs, which becomes a necessity to counterbalance statutory and political price cuts.

B. Policy and Legal Strategy: Proactive Engagement

1. Neutralizing the Best Price Barrier: Dedicate significant legal and governmental affairs resources to securing definitive statutory or regulatory safe harbors that explicitly neutralize the Medicaid Best Price and Anti-Kickback Statute constraints for outcomes-based and indication-specific contracts.⁹ Clarity on these policies is paramount for widespread VBP adoption.

2. Harmonizing Global Market Access: Establish a centralized global function responsible for coordinating market access sequencing. This team must ensure that U.S. price negotiations do not inadvertently trigger adverse external reference pricing decisions from globally influential HTA agencies in Europe, Canada, and Australia.¹⁹

C. Market Access Strategy: Evidence and Differentiation

1. Build the Global Core Value Dossier: Standardize evidence generation early in Phase III trials to meet the methodological rigor of the most demanding HTA agencies globally (e.g., NICE).²³ Focus on proactive head-to-head comparative effectiveness studies against optimal therapeutic alternatives.

2. Targeted RWE for Vulnerability: Prioritize the design and execution of Real-World Evidence studies that specifically document superior clinical and economic benefits for patient subpopulations designated in the IRA (the elderly, disabled, and terminally ill).⁸ This evidence is necessary to establish an undeniable narrative of therapeutic advance for CMS negotiation.

3. Operationalize VBP Technology: View investment in integrated RWE, AI, and claims data infrastructure as a strategic, mandatory commercial expenditure. This technological foundation is essential for moving high-volume, high-value therapies from traditional list price models to scalable, auditable outcomes-based risk-sharing agreements.³²

VII. Conclusion: A Call for Structural Adaptation

The convergence of the Inflation Reduction Act and the Most-Favored-Nation framework represents a paradigm shift, definitively marking the end of the U.S. as a purely premium-priced market driven solely by patent exclusivity. The resulting market is now characterized by unprecedented pricing volatility, accelerated loss of exclusivity, and the institutionalization of federal HTA.

The strategic success of global biopharmaceutical leaders hinges upon deep structural adaptation. Innovation must now be defended through the intellectual rigor of evidence, rather than relying on historical regulatory inertia. Companies that succeed will be those that transform their R&D into a global HTA evidence engine, master complex segmented pricing strategies such as Indication-Specific Pricing, and operationalize outcomes-based contracts at scale to mitigate the severe financial compression introduced by these twin regulatory headwinds. Failure to adapt to this new environment risks significant portfolio devaluation and a long-term erosion of R&D funding capacity.

portfolio devaluation and a long-term erosion of R&D funding capacity.

Sources:

1. Most-Favored-Nation Prescription Drug Pricing Executive Order: Legal Issues

2. The Impact of the Inflation Reduction Act on the Economic Lifecycle of a Pharmaceutical Brand - IQVIA

3. Negotiated Prices Take Effect for Ten Drugs in 2026 - Medicare Rights Center

4. U.S. MFN Drug Pricing 2025: Impact & Strategies for Pharma - Trinity Life Sciences

5. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients - The White House

6. TrumpRx: What Pharmacies and Plan Sponsors Need to Know

7. Health Technology Assessment, Again: A Transparent, Evidence-Based Approach For CMS Drug Price Negotiations

8. FAQs about the Inflation Reduction Act's Medicare Drug Price Negotiation Program - KFF

9. Medicaid VBP Rule May Facilitate Drug Contracts, But Questions Remain

10. CMS Issues New Guidance on Variable Best Price Reporting under the Medicaid Drug Rebate Program - Georgetown Center for Children and Families

11. Medicare Announces Results of First Round of Historic Drug Price Negotiations, Effective 2026

12. Mintz IRA Update — Under Pressure: The Trump Administration's Drug Pricing Executive Orders

13. Chamber Urges Trump to Refocus Drug Pricing Efforts - IPWatchdog.com

14. Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices | AJMC

15. Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices

16. Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

17. Economy Statement for the Treasury Borrowing Advisory Committee

18. Pharmaceutical Innovation and the Inflation Reduction Act | ATI Advisory

19. Inflation Reduction Act: Global Implications for Pricing and Reimbursement - ISPOR

20. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study - NIH

21. 2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

22. ICER's Reference Case for Economic Evaluations: Elements and Rationale

23. Variability of Comparator Drugs in Ex-US HTAs Offers Lessons for the IRA

24. Navigating change: a comparative analysis of health technology assessment reforms across agencies – processes, drivers, and interdependencies - NIH

25. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia - NIH

26. Value-Based Contracting in Pharma: Models & Challenges | IntuitionLabs

27. Innovative Contracting: Value-Based Strategies and Global Trends - AMCP Learn |

28. Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation

29. The New Pharma Playbook: A 2025-2030 Guide to Market Domination in a Data-Driven World - DrugPatentWatch

30. Overcoming the Legal and Regulatory Hurdles to Value-Based Payment Arrangements for Medical Products - Duke-Margolis Center for Health Policy

31. Indication-specific pricing of pharmaceuticals in the United States Health Care System - ICER

32. Innovation is revolutionizing outcome-driven payer contracting in US pharma and biotech - Simon-Kucher

33. Framework for FDA's Real-World Evidence Program

34. A Strategic Approach to Cost in Biopharma | BCG